New registry tracks rezdiffra safety for moms and babies
NCT ID NCT07541469
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks the safety of the liver drug Rezdiffra (resmetirom) in women with NASH who take it while pregnant or breastfeeding. Researchers will follow about 10 women and their infants up to 12 months old to check for birth defects, growth problems, and other health issues. No new treatment is given—it simply collects real-world information to better understand risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Madrigal Pharmaceuticals
RECRUITINGWest Conshohocken, Pennsylvania, 19428, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a once-daily pill help children with fatty liver disease?
- Could a common sugar fuel liver damage?
- Can eating only during an 8-10 hour window help liver cancer patients?
- Could a quick liver scan replace needle biopsies for MASH in diabetics?
- New pill could stop liver scarring in MASH patients
- Exercise may fight fatty liver in seniors, new study hopes to prove